Boston University Archives - Carey Danis & Lowe

Zofran Litigation: Drug Caused Cleft Palate say Mississippi Parents

By | Pharmaceutical litigation, Uncategorized, Zofran

zofran-birth-defectsNew lawsuits allege that the anti-nausea drug, Zofran is to blame for cleft palate in infants whose mothers took the drug at the beginning of pregnancies.

One Mississippi family claims that exposure to Zofran during the first trimester caused their daughter’s soft cleft palate. The lawsuits, filed against drug behemoth GlaxoSmithKline, were issued in the US District Court for the Southern District of Mississippi on July 17, 2015. It’s believed that they are the first parents to file in the Mississippi Federal Court.

In January 2015, the Mississippi mother gave birth to a child diagnosed with soft cleft palate. With this disability, the roof of the mouth is split, which affects feeding, speech, breathing and language development. There’s no history of birth defects in this family and a previous child was born healthy and without congenital problems.

Are there links between Zofran and Cleft Palate?

While the drug is prescribed as an “off label” treatment for morning sickness, its efficacy hasn’t been proven and recent research has found a link between the drug and birth defects.

A paper published by researchers at Harvard and Boston University, discovered a 2.37 times increase in the chance for cleft palate after prenatal exposure to Zofran.

While 34 families have filed Zofran lawsuits in Federal Court, that number hardly compares to the amount of women who have been exposed to the pharmaceutical during pregnancy. Zofran use has soared to over 1 million prescriptions every year.

Carey Danis & Lowe can help with Zofran Birth Defect Lawsuits

If you or someone you love used Zofran during the first trimester of pregnancy, and a child was born with birth defects, then you or your loved one may be eligible to receive compensation.

Contact Carey Danis & Lowe for a free legal consultation. One of our Zofran lawyers will walk you through your litigation options, and whether filing a Zofran birth defect lawsuit is the right path for you.

Call Carey Danis & Lowe at 800.721.2519, or complete a confidential personal injury claim form.

Low Testosterone Ads & Disease Mongering

By | Pharmaceutical litigation, Testosterone, Uncategorized

testosteronegellawsuitTestosterone ads spread the word about low testosterone, or low T. And to some, low T is an invented disease.

In an editorial recently published in the Journal of the American Geriatrics Society, two men’s health experts expressed concerns about direct-to-consumer ads for testosterone products, like AndroGel and Axiron.

Thomas Perls, a Boston University professor and Boston Medical Center geriatrician, and David Handelsman, a University of Sydney professor, authored the editorial.

Perls and Handelsman consider direct-to-consumer ads to be “’disease mongering’”, since the ads treat male aging as a curable health condition, as opposed to a normal part of life.

The two authors have called for a ban on testosterone ads.

Why the Worry about Ads?

If there weren’t serious testosterone side effects, like heart attack and stroke, then testosterone ads wouldn’t be a concern. However, researchers have discovered a strong link between testosterone use in older males and cardiovascular problems, including heart attack and stroke.

Perls and Handelsman may be correct in calling for a ban on testosterone ads.

Free Case Evaluation

Carey Danis & Lowe is a personal injury law firm that represents men who have been injured by testosterone gel. We encourage you to contact our law firm today if you experienced an injury after using testosterone gel.

During our free case evaluations, one of our personal injury lawyers will guide you through your legal options, compensation eligibility, and if applicable, filing a testosterone lawsuit.

Contact Carey Danis & Lowe by phone at 800.721.2519, or complete a confidential personal injury claim form. We look forward to offering you any assistance that we can.